在GRADE比较有效性临床试验中,接近SLC2A2的常见遗传变异和对glimepiride的血糖反应
Josephine H Li1,2,3,4, Lukasz Szczerbinski2,3,4,5, Mark Tripputi6
1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
medRxiv : the preprint server for health sciences
|November 24, 2025
概括
遗传变异会影响2型糖尿病的治疗反应. 这种SLC2A2基因变异rs1905505与硫氨基酸药物glimepiride的有效性降低有关.
科学领域:
- 药物基因组学 药物基因组学
- 遗传学 是一个遗传学.
- 内分泌学 在内分泌学.
背景情况:
- 优化2型糖尿病的二线治疗是复杂的,因为患者的反应不同.
- 药物基因组方法可以帮助个性化治疗策略.
研究的目的:
- 识别对常见的2型糖尿病药物的血糖反应的遗传预测因素.
- 通过GRADE研究来调查遗传变异在治疗疗效中的作用.
主要方法:
- 在GRADE研究队列中进行了药物基因组全基因组关联研究 (GWAS).
- 分析了与胰岛素glargine,glimepiride,liraglutide和sitagliptin的血糖反应相关的遗传变异.
- 使用斑马鱼的功能研究验证的结果.
主要成果:
- 确定了21个与治疗反应相关的全基因组显著位置.
- 接近SLC2A2的变体rs1905505与增加格莱梅皮里德治疗失败的风险有关,特别是在非洲血统的人群中.
- rs1905505载体显示β细胞功能受损,对硫基尿素挑战的反应降低.
结论:
- 遗传变异显著影响了对2型糖尿病药物的血糖反应.
- SLC2A2是硫基尿素反应的关键决定因素,突出其作为药物基因组目标的潜力.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Oral Hypoglycemic Agents: Sulfonylureas
733
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
733
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


